Evolving Indications for Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Other Plasma Cell Disorders

  • Guido TricotEmail author
  • Maurizio Zangari
  • Roberto Sorasio
  • Benedetto Bruno
Part of the Cancer Treatment and Research book series (CTAR, volume 144)


Multiple myeloma is a differentiated clonal B-cell tumor, consisting in the early stages of the disease of slowly proliferating malignant plasma cells (myeloma cells). It is the second most common hematologic malignancy after non-Hodgkin’s lymphoma. Normal plasma cells are very hardy cells and usually the only type of cell to survive the effects of myelosuppressive chemotherapy and radiation. The plasma cells have abnormal cytogenetics even at the stage of monoclonal gammopathy of undetermined significance, as evidenced by fluorescence in-situ hybridization (FISH) or cIg/DNA content [1, 2, 3]. Before it transforms to an aggressive disease, which is typically associated with extramedullary disease, immature morphology of the myeloma cells, rapid proliferation, and increase in LDH, the disease is entirely bone marrow stroma-dependent and, therefore, contained within the active hematopoietic bone marrow, although breakout lesions from the bone can be seen. The myeloma cell...


Hematopoietic Stem Cell Transplantation Total Body Irradiation Peripheral Blood Stem Cell Allogeneic Hematopoietic Stem Cell Transplantation Chronic GvHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995;86:3915.PubMedGoogle Scholar
  2. 2.
    Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995;90:693.PubMedGoogle Scholar
  3. 3.
    Latreille J, Barlogie B, Johnston D, et al. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 1982;59:43.PubMedGoogle Scholar
  4. 4.
    Klein B, Zhang XG, Lu ZY, et al. Interleukin-6 in human multiple myeloma. Blood 1995;85:863.PubMedGoogle Scholar
  5. 5.
    Tinhofer I, Marschitz I, Henn T, et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610.PubMedGoogle Scholar
  6. 6.
    Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856.PubMedGoogle Scholar
  7. 7.
    Jundt F, Probsting K, Anagnostopoulos I, et al. Jagged 1-Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511.PubMedGoogle Scholar
  8. 8.
    Nefedova Y, Cheng P, Alsina M, et al. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503.PubMedGoogle Scholar
  9. 9.
    Rebollo A, Martinez AC. Ras proteins: recent advances and new functions. Blood 1999;94:2971.PubMedGoogle Scholar
  10. 10.
    Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587.PubMedGoogle Scholar
  11. 11.
    Wang CY, Mayo MW, Korneluk RG, et al. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680.PubMedGoogle Scholar
  12. 12.
    Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658.PubMedGoogle Scholar
  13. 13.
    Bakkus MH, Van Riet I, De Greef C, et al. The clonogenic precursor cell in multiple myeloma. Leuk Lymphoma. 1995;18:221.PubMedGoogle Scholar
  14. 14.
    Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol. 1995;155:2487.PubMedGoogle Scholar
  15. 15.
    Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103(6):2332–6.PubMedGoogle Scholar
  16. 16.
    Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med. 2006;203(8):1859–65.PubMedGoogle Scholar
  17. 17.
    Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007;104(10):4048–53.Google Scholar
  18. 18.
    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822.PubMedGoogle Scholar
  19. 19.
    Moreau P, Fiere D, Bezwoda WR, et al. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol. 1997;15:660–6.PubMedGoogle Scholar
  20. 20.
    Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience. Semin Hematol. 2001;38:209–18.PubMedGoogle Scholar
  21. 21.
    Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996;88:838.PubMedGoogle Scholar
  22. 22.
    Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298.PubMedGoogle Scholar
  23. 23.
    Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588–96.PubMedGoogle Scholar
  24. 24.
    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86–9.PubMedGoogle Scholar
  25. 25.
    Monconduit M, Menard JF, Michaux JL, et al. VAD or VMBCP in severe multiple myeloma. The Groupe d’Etudes et de Recherche sur le Myélome (GERM). Br J Haematol. 1992;80:199–204.PubMedGoogle Scholar
  26. 26.
    Rajkumar SV, Blood E, Vesole D, et al. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–6.PubMedGoogle Scholar
  27. 27.
    Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165–72.PubMedGoogle Scholar
  28. 28.
    Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158–64.PubMedGoogle Scholar
  29. 29.
    Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789.PubMedGoogle Scholar
  30. 30.
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–7.PubMedGoogle Scholar
  31. 31.
    Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.PubMedGoogle Scholar
  32. 32.
    Fermand JP, Katsahian S, Divine M, et al. Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.PubMedGoogle Scholar
  33. 33.
    Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.PubMedGoogle Scholar
  34. 34.
    Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.PubMedGoogle Scholar
  35. 35.
    Sirohi B, Powles R, Mehta J, et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant. 2005;36:19–24.PubMedGoogle Scholar
  36. 36.
    Hahn T, Wolff SN, Czuczman M, et al. American Society for Blood and Marrow Transplantation (ASBMT). The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2003;9:667.PubMedGoogle Scholar
  37. 37.
    Morris TC, Velangi M, Jackson G, et al. Northern Ireland Regional Haematology Group; Northern Regional Haematologists Group; Clinical Trials Committee of The British Scoiety for Blood and Marrow Transplantation. Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. Br J Haematol. 2005;128:510–2.PubMedGoogle Scholar
  38. 38.
    Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.PubMedGoogle Scholar
  39. 39.
    Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731.PubMedGoogle Scholar
  40. 40.
    Desikan KR, Tricot G, Dhodapkar M, et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant. 2000;25:483.PubMedGoogle Scholar
  41. 41.
    Björkstrand B, Svensson H, Ljungmand P, et al. 2522 autotransplants in multiple myeloma: a registry study from the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; (Abstract no. 1862).Google Scholar
  42. 42.
    Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004;100:2607–12.PubMedGoogle Scholar
  43. 43.
    Corradini P, Voena C, Astolfi M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995;85:1596.PubMedGoogle Scholar
  44. 44.
    Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996;87:805.PubMedGoogle Scholar
  45. 45.
    Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992;80:1818.PubMedGoogle Scholar
  46. 46.
    Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85.PubMedGoogle Scholar
  47. 47.
    Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068.PubMedGoogle Scholar
  48. 48.
    Gertz MA, Witzig TE, Pineda AA, et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19:337.PubMedGoogle Scholar
  49. 49.
    Gahrton G, Svensson H, Björkstrand B, et al. Syngeneic transplantation in multiple myeloma—a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999;24:741–5.PubMedGoogle Scholar
  50. 50.
    Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858.PubMedGoogle Scholar
  51. 51.
    Attal M, Harousseau JL, Facon T, et al. InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.PubMedGoogle Scholar
  52. 52.
    Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434–41.PubMedGoogle Scholar
  53. 53.
    Morris C, Iacobelli S, Brand R, et al. Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol. 2004;22:1674–81.PubMedGoogle Scholar
  54. 54.
    Alexanian R, Dimopoulos MA, Hester J, et al. Early myeloablative therapy for multiple myeloma. Blood 1994;84:4278–82.PubMedGoogle Scholar
  55. 55.
    Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology – an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998;91:2501.PubMedGoogle Scholar
  56. 56.
    Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161.PubMedGoogle Scholar
  57. 57.
    Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413.PubMedGoogle Scholar
  58. 58.
    Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51–4.PubMedGoogle Scholar
  59. 59.
    Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant. 2003;32:1135–43.PubMedGoogle Scholar
  60. 60.
    Jantunen E, Kuittinen T, Penttila K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37:917–22.PubMedGoogle Scholar
  61. 61.
    Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autlogous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol. 2006;24: (Abstract).Google Scholar
  62. 62.
    Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–52.PubMedGoogle Scholar
  63. 63.
    Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–9.PubMedGoogle Scholar
  64. 64.
    Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–8.PubMedGoogle Scholar
  65. 65.
    Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006;91:1555–8.PubMedGoogle Scholar
  66. 66.
    Knudsen LM, Nielsen B, Gimsing P, et al. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27–33.PubMedGoogle Scholar
  67. 67.
    Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54.PubMedGoogle Scholar
  68. 68.
    Greipp P, San Miguel J, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412.PubMedGoogle Scholar
  69. 69.
    Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250.PubMedGoogle Scholar
  70. 70.
    Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008.PubMedGoogle Scholar
  71. 71.
    Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol. 2004;125:24–30.PubMedGoogle Scholar
  72. 72.
    Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041.PubMedGoogle Scholar
  73. 73.
    Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569.PubMedGoogle Scholar
  74. 74.
    Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579.PubMedGoogle Scholar
  75. 75.
    Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001;98:2266.PubMedGoogle Scholar
  76. 76.
    Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98:217.PubMedGoogle Scholar
  77. 77.
    Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol. 2006;24:e4–5.PubMedGoogle Scholar
  78. 78.
    Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–8.PubMedGoogle Scholar
  79. 79.
    Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and –17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–40.PubMedGoogle Scholar
  80. 80.
    Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020–8.PubMedGoogle Scholar
  81. 81.
    Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802.PubMedGoogle Scholar
  82. 82.
    Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358.PubMedGoogle Scholar
  83. 83.
    Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–84.PubMedGoogle Scholar
  84. 84.
    Shaughnessy JD, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007;137:530–6.PubMedGoogle Scholar
  85. 85.
    Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007;109:4995–5001.PubMedGoogle Scholar
  86. 86.
    Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–32.PubMedGoogle Scholar
  87. 87.
    Fermand JP, Ravaud P, Chevret S, et al. High dose therapy and autologous blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3191–6.Google Scholar
  88. 88.
    Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better support care and double transplants. Blood 1994;84:950–6.PubMedGoogle Scholar
  89. 89.
    Vesole D, Crowley J, Catchatourian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clinic Oncol. 1999;17:2173–9.Google Scholar
  90. 90.
    Rajkumar SV, Fonseca R, Lacy MQ, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999;23:1267–72.PubMedGoogle Scholar
  91. 91.
    Pineda-Roman M, Haessler J, Hollmig K, et al. High-dose melphalan (MEL) based autotransplants (AT) for multiple myeloma (MM): the Arkansas experience since 1989 in more than 2,800 patients. J Clin Oncol. 2007;25: (Abstract 8043).Google Scholar
  92. 92.
    Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clinic Oncol. 2003;21:2723–9.Google Scholar
  93. 93.
    Tricot G, Reiner M, Zangari M, et al. Melphalan 200 mg/m2 (MEL 200) and MEL 140/DT-PACE are equally effective in multiple myeloma (MM), while the latter is less toxic. Blood 2005;106: (Abstract 839).Google Scholar
  94. 94.
    Mansi JL, Cunningham D, Viner C, et al. Repeat administration of high dose melphalan in relapsed myeloma. Br J Cancer. 1993;68:983–7.PubMedGoogle Scholar
  95. 95.
    Tricot G, Jagannath S, Vesole DH, et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995;16:7–11.PubMedGoogle Scholar
  96. 96.
    Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176–85.PubMedGoogle Scholar
  97. 97.
    Lee CK, Barlogie B, Fassas A, et al. Third Autotransplant for the management of 98 patients among 1358 who had received prior tandem autotransplants: benefit apparent when 2nd to 3rd transplant interval exceeds 3 years. Blood 104: (Abstract 540).Google Scholar
  98. 98.
    Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol. 2006;81:426–31.PubMedGoogle Scholar
  99. 99.
    Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–98.PubMedGoogle Scholar
  100. 100.
    Bruno B, Giaccone L, Rotta M, et al. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 2005;19:1729–38 (Review).PubMedGoogle Scholar
  101. 101.
    Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant. 1998;22:835–43 (Review).PubMedGoogle Scholar
  102. 102.
    Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med. 1991;325:1267–73.PubMedGoogle Scholar
  103. 103.
    Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312–22.PubMedGoogle Scholar
  104. 104.
    Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787–93.PubMedGoogle Scholar
  105. 105.
    Bensinger WI. Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci. 2007;12:4384–92.PubMedGoogle Scholar
  106. 106.
    Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755–60.PubMedGoogle Scholar
  107. 107.
    Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447–54.PubMedGoogle Scholar
  108. 108.
    Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol. 2001;38:243–9.PubMedGoogle Scholar
  109. 109.
    Reece DE, Shepherd JD, Klingemann HO, et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:117–23.PubMedGoogle Scholar
  110. 110.
    Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98:934–9.PubMedGoogle Scholar
  111. 111.
    Kulkarni S, Powles RL, Treleaven JO, et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant. 1999;23:675–80.PubMedGoogle Scholar
  112. 112.
    Le Blanc R, Montminy-Metivier S, Belanger R, et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 2001;28:841–8.PubMedGoogle Scholar
  113. 113.
    Couban S, Stewart AK, Loach D, et al. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant. 1997;19:783–9.PubMedGoogle Scholar
  114. 114.
    Varterasian M, Janakiraman N, Karanes C, et al. Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol. 1997;20:462–6.PubMedGoogle Scholar
  115. 115.
    Russell NH, Miflin G, Stainer C, et al. Allogeneic bone marrow transplant for multiple myeloma. Blood 1997;89:2610–1 (Letter).PubMedGoogle Scholar
  116. 116.
    Cavo M, Bandini G, Benni M, et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 1998;22:27–32.PubMedGoogle Scholar
  117. 117.
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the European Group for Blood Marrow Transplantation. Br J Haematol. 1998;102:1115–23.PubMedGoogle Scholar
  118. 118.
    Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17:208–15.PubMedGoogle Scholar
  119. 119.
    Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927–9.PubMedGoogle Scholar
  120. 120.
    Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 1994–1998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209–16.PubMedGoogle Scholar
  121. 121.
    Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711–8.PubMedGoogle Scholar
  122. 122.
    Kuruvilla J, Shepherd JD, Sutherland HJ, et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2007;13:925–31.PubMedGoogle Scholar
  123. 123.
    Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol. 2007;20:219–29 (Review).PubMedGoogle Scholar
  124. 124.
    Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GvHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110:1397–400.PubMedGoogle Scholar
  125. 125.
    Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005;11:85–92.PubMedGoogle Scholar
  126. 126.
    Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415–9.PubMedGoogle Scholar
  127. 127.
    Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003;120:44–52.PubMedGoogle Scholar
  128. 128.
    Barlogie B Jr, Shaughnessy JD. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol. 2002;76 Suppl 1:337–9.PubMedGoogle Scholar
  129. 129.
    Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–95.PubMedGoogle Scholar
  130. 130.
    Matsui S, Yamanaka T, Barlogie B, et al. Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Stat Med. 2008;27:1106–20.Google Scholar
  131. 131.
    Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048–54.PubMedGoogle Scholar
  132. 132.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–400.PubMedGoogle Scholar
  133. 133.
    Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:77–84.PubMedGoogle Scholar
  134. 134.
    Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant. 2003:9;257–265.PubMedGoogle Scholar
  135. 135.
    Einsele H, Schafer HJ, Hebart HP, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003;121:411–8.PubMedGoogle Scholar
  136. 136.
    Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002:30;367–73.PubMedGoogle Scholar
  137. 137.
    Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 2005:36;963–9.PubMedGoogle Scholar
  138. 138.
    Bruno B, Sorasio R, Patriarca F, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol. 2007;78:330–7.PubMedGoogle Scholar
  139. 139.
    Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;31:73–80.PubMedGoogle Scholar
  140. 140.
    Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919–24.PubMedGoogle Scholar
  141. 141.
    Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005;29:961–6.PubMedGoogle Scholar
  142. 142.
    Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–94.PubMedGoogle Scholar
  143. 143.
    Wheatley K, Gray R. Commentary: Mendelian randomization—an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol. 2004;33:15–7.PubMedGoogle Scholar
  144. 144.
    Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635–42.PubMedGoogle Scholar
  145. 145.
    Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56–62.PubMedGoogle Scholar
  146. 146.
    Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–40.PubMedGoogle Scholar
  147. 147.
    Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–80.PubMedGoogle Scholar
  148. 148.
    Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103:4056–61.PubMedGoogle Scholar
  149. 149.
    Bruno B, Rotta, F. Patriarca, et al. A comparison of allografting with autografting for newly-diagnosed myeloma. N Engl J Med. 2007;356:1110–20.PubMedGoogle Scholar
  150. 150.
    Giaccone L, Patriarca F, Rotta M, et al. Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: the GITMO (Gruppo Italiano Trapianto di Midollo) experience. Haematologica 2007;92(s1):s4 Abs 0403.Google Scholar
  151. 151.
    Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016–20.PubMedGoogle Scholar
  152. 152.
    Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196–8.PubMedGoogle Scholar
  153. 153.
    Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800–1.PubMedGoogle Scholar
  154. 154.
    Aschan J, Lonnqvist B, Ringden O, et al. Graft-versus-myeloma effect. Lancet 1996;348:346 (Letter).PubMedGoogle Scholar
  155. 155.
    Libura J, Hoffmann T, Passweg J, et al. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 1999;24:925–7.PubMedGoogle Scholar
  156. 156.
    Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.PubMedGoogle Scholar
  157. 157.
    Zeiser R, Bertz H, Spyridonidis A, et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 2004;34:923–8.PubMedGoogle Scholar
  158. 158.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4206–11.PubMedGoogle Scholar
  159. 159.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031–7.PubMedGoogle Scholar
  160. 160.
    Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362–4.PubMedGoogle Scholar
  161. 161.
    van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37:1135–41.PubMedGoogle Scholar
  162. 162.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.PubMedGoogle Scholar
  163. 163.
    Hale O, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69–76.PubMedGoogle Scholar
  164. 164.
    Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol. 2003;21:1728–33.PubMedGoogle Scholar
  165. 165.
    Preijers FWMB, van HennikPB, Schattenberg A, et al. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. Bone Marrow Transplant. 1999;23:1061–70.PubMedGoogle Scholar
  166. 166.
    Levenga H, Levison-Keating S, Schattenberg AV, et al. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant. 2007;40:355–9.PubMedGoogle Scholar
  167. 167.
    Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006;91:837–9.PubMedGoogle Scholar
  168. 168.
    van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006;107:3415–6.PubMedGoogle Scholar
  169. 169.
    Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361–3.PubMedGoogle Scholar
  170. 170.
    Kroger N, Zabelina T, Ayuk F, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 2006;34:770–5.PubMedGoogle Scholar
  171. 171.
    Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353:1321–31. Erratum in: N Engl J Med. 2006;354:884.Google Scholar
  172. 172.
    Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007;109:1103–12.PubMedGoogle Scholar
  173. 173.
    Siegel S, Wagner A, Friedrichs B, et al. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol. 2006;76:6935–44.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Guido Tricot
    • 1
    Email author
  • Maurizio Zangari
  • Roberto Sorasio
  • Benedetto Bruno
  1. 1.Professor of MedicineUniversity of Utah School of MedicineSalt Lake CityUSA

Personalised recommendations